Qilian International Holding Group Limited (QLI)

Market Cap	42.54M
Revenue (ttm)	57.10M
Net Income (ttm)	3.15M
Shares Out	35.75M
EPS (ttm)	0.09
PE Ratio	13.22
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,370
Open	1.20
Previous Close	1.16
Day's Range	1.19 - 1.22
52-Week Range	1.01 - 4.04
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About QLI

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce co...

• Industry: Drug Manufacturers-Specialty & Generic
• IPO Date: Jan 12, 2021
• Employees: 283
• Stock Exchange: NASDAQ
• Ticker Symbol: QLI

Full Company Profile

Financial Performance

In 2021, QLI's revenue was $57.10 million, an increase of 14.12% compared to the previous year's $50.03 million. Earnings were $3.15 million, a decrease of -37.74%.

Financial Statements